{"id":965101,"date":"2026-05-20T07:07:17","date_gmt":"2026-05-20T11:07:17","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026\/"},"modified":"2026-05-20T07:07:17","modified_gmt":"2026-05-20T11:07:17","slug":"biolinerx-to-report-first-quarter-2026-results-on-may-27-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026\/","title":{"rendered":"BioLineRx to Report First Quarter 2026 Results on May 27, 2026"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p class=\"prntac\">\n        <i>Management to Hold Conference Call at 8:30 a.m. EDT<\/i>\n      <\/p>\n<p>\n        <span class=\"legendSpanClass\">TEL AVIV, Israel<\/span>, <span class=\"legendSpanClass\">May 20, 2026<\/span> \/PRNewswire\/ &#8212; BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the quarter ended March 31, 2026 on Wednesday, May 27, 2026, before the U.S. markets open.<\/p>\n<div id=\"prni_dvprnejpg4ce6left\" dir=\"ltr\" style=\"width: 100%;text-align: left\">\n        <img decoding=\"async\" id=\"prnejpg4ce6left\" title=\"BioLineRx Ltd Logo\" src=\"https:\/\/mma.prnewswire.com\/media\/2154863\/BioLineRx_Ltd_Logo.jpg\" alt=\"BioLineRx Ltd Logo\" align=\"middle\" \/>\n      <\/div>\n<p>The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer.<\/p>\n<p>To access the conference call, please dial +1-888-407-2553 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the <a href=\"https:\/\/ir.biolinerx.com\/events\/event-details\/biolinerx-report-first-quarter-2026-results-may-27-2026\" target=\"_blank\" rel=\"nofollow\">event page<\/a> on the Company&#8217;s website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. The call replay will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available until May 28, 2026; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.<\/p>\n<p>\n        <b>About BioLineRx<\/b>\n      <\/p>\n<p>BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX)\u00a0is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The Company&#8217;s lead development asset is GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other solid tumors, for which a Phase 1\/2a clinical trial has been initiated in the first quarter of 2026. GLIX1 is being developed under a collaboration with Hemispherian AS.<\/p>\n<p>The Company&#8217;s first approved product, APHEXDA\u00ae (motixafortide), is indicated in the\u00a0U.S.\u00a0for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by\u00a0Ayrmid Ltd.\u00a0(globally, except\u00a0Asia) and Gloria Biosciences (in\u00a0Asia).\u00a0BioLineRx has retained the rights to develop motixafortide in solid tumors, including metastatic pancreatic cancer (PDAC), and has a Phase 2b PDAC trial currently ongoing under a collaboration with\u00a0Columbia University.<\/p>\n<p>Learn more about who we are, what we do, and how we do it at\u202f<a href=\"http:\/\/www.biolinerx.com\/\" target=\"_blank\" rel=\"nofollow\">www.biolinerx.com<\/a>, or on\u202f<a href=\"https:\/\/www.linkedin.com\/company\/112275\/admin\/\" target=\"_blank\" rel=\"nofollow\">LinkedIn<\/a>.<\/p>\n<p>\n        <b>CONTACTS:<\/b>\n      <\/p>\n<p>\n        <u>United States<br \/><\/u>Chuck Padala<br \/>LifeSci Advisors, LLC<br \/><a href=\"mailto:IR@biolinerx.com\" target=\"_blank\" rel=\"nofollow\">IR@biolinerx.com<\/a><\/p>\n<p>\n        <u>Israel<br \/><\/u>Moran Meir<br \/>LifeSci Advisors, LLC<br \/><a href=\"mailto:moran@lifesciadvisors.com\" target=\"_blank\" rel=\"nofollow\">moran@lifesciadvisors.com<\/a><\/p>\n<p>Logo: <a href=\"https:\/\/mma.prnewswire.com\/media\/2154863\/BioLineRx_Ltd_Logo.jpg\" target=\"_blank\" rel=\"nofollow\">https:\/\/mma.prnewswire.com\/media\/2154863\/BioLineRx_Ltd_Logo.jpg<\/a><\/p>\n<p>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=LN64095&amp;sd=2026-05-20\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026-302777565.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026-302777565.html<\/a><\/p>\n<p>SOURCE BioLineRx Ltd.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LN64095&amp;Transmission_Id=202605200700PR_NEWS_USPR_____LN64095&amp;DateId=20260520\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, May 20, 2026 \/PRNewswire\/ &#8212; BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the quarter ended March 31, 2026 on Wednesday, May 27, 2026, before the U.S. markets open. The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer. To access the conference call, please dial +1-888-407-2553 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company&#8217;s website. Please allow extra &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BioLineRx to Report First Quarter 2026 Results on May 27, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-965101","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BioLineRx to Report First Quarter 2026 Results on May 27, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioLineRx to Report First Quarter 2026 Results on May 27, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, May 20, 2026 \/PRNewswire\/ &#8212; BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the quarter ended March 31, 2026 on Wednesday, May 27, 2026, before the U.S. markets open. The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer. To access the conference call, please dial +1-888-407-2553 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company&#8217;s website. Please allow extra &hellip; Continue reading &quot;BioLineRx to Report First Quarter 2026 Results on May 27, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-20T11:07:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2154863\/BioLineRx_Ltd_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BioLineRx to Report First Quarter 2026 Results on May 27, 2026\",\"datePublished\":\"2026-05-20T11:07:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026\\\/\"},\"wordCount\":389,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2154863\\\/BioLineRx_Ltd_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026\\\/\",\"name\":\"BioLineRx to Report First Quarter 2026 Results on May 27, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2154863\\\/BioLineRx_Ltd_Logo.jpg\",\"datePublished\":\"2026-05-20T11:07:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2154863\\\/BioLineRx_Ltd_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2154863\\\/BioLineRx_Ltd_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioLineRx to Report First Quarter 2026 Results on May 27, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioLineRx to Report First Quarter 2026 Results on May 27, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026\/","og_locale":"en_US","og_type":"article","og_title":"BioLineRx to Report First Quarter 2026 Results on May 27, 2026 - Market Newsdesk","og_description":"PR Newswire Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, May 20, 2026 \/PRNewswire\/ &#8212; BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the quarter ended March 31, 2026 on Wednesday, May 27, 2026, before the U.S. markets open. The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer. To access the conference call, please dial +1-888-407-2553 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company&#8217;s website. Please allow extra &hellip; Continue reading \"BioLineRx to Report First Quarter 2026 Results on May 27, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-20T11:07:17+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2154863\/BioLineRx_Ltd_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BioLineRx to Report First Quarter 2026 Results on May 27, 2026","datePublished":"2026-05-20T11:07:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026\/"},"wordCount":389,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2154863\/BioLineRx_Ltd_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026\/","name":"BioLineRx to Report First Quarter 2026 Results on May 27, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2154863\/BioLineRx_Ltd_Logo.jpg","datePublished":"2026-05-20T11:07:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2154863\/BioLineRx_Ltd_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2154863\/BioLineRx_Ltd_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BioLineRx to Report First Quarter 2026 Results on May 27, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/965101","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=965101"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/965101\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=965101"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=965101"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=965101"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}